The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
N-Methyl-d-Aspartic Acid Receptor Expression in the Dorsolateral Prefrontal Cortex of Elderly Patients With Schizophrenia
Abstract
OBJECTIVE: The N-methyl-D-aspartic acid (NMDA) class of glutamate receptors has received attention in the pathophysiology of schizophrenia because of the similarity between some schizophrenic symptoms and symptoms caused by NMDA antagonists. To determine if NMDA receptor abnormalities were present at the mRNA level, expression of NMDA receptor (NR) subunits NR(1), NR(2A), and NR(2B) was measured in specimens from the dorsolateral prefrontal cortex and the occipital cortex of elderly patients with schizophrenia and normal elderly subjects. METHOD: Postmortem specimens from antemortem assessed and diagnosed elderly patients with schizophrenia (N=26) were compared with those from a neuropathologically and neuropsychiatrically normal elderly comparison group (N=13) and from patients with Alzheimer's disease (N=10). The mRNA expression of the NR(1), NR(2A), and NR(2B) subunits and of postsynaptic density 95 (PSD-95), a protein associated with postsynaptic NMDA receptors, was studied with quantitative real-time reverse transcriptase polymerase chain reaction. RESULTS: Expression of NR(1) and NR(2A) but not NR(2B) subunits was higher in the dorsolateral prefrontal cortex and the occipital cortex of patients with schizophrenia than in the normal and Alzheimer's disease groups. In contrast, NR(1) expression was significantly lower in the Alzheimer's disease group. Occipital cortex expression of PSD-95 was higher in the schizophrenic subjects and correlated strongly with the expression of NR(2A) and NR(2B) in both cortical regions and with expression of NR(1) in the occipital cortex. These results were not influenced by neuroleptic exposure history, postmortem interval, or age of the subject. CONCLUSIONS: NMDA receptor subunits are abnormally expressed in elderly patients with schizophrenia. The disproportionate expression of the NR(1) and NR(2A) subunits relative to NR(2B) expression may have implications for the pathophysiology of schizophrenia and the sensitivity of schizophrenic patients to glutamate and glutamatergic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“Observations of abnormalities in markers of glutamatergic neurotransmission in the hippocampus and the entorhinal, cingulate, orbital, and prefrontal cortices of patients with schizophrenia (3, 13, 28–43), the critical role of glutamatergic systems in learning and memory (44, 45), and the clear evidence for the neurot…”
BackgroundThe neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
Migaud, M., Charlesworth, P., Dempster, M., Webster, L. C., Watabe, A. M., Makhinson, M., He, Y., Ramsay, M. F., Morris, R. G. M., Morrison, J. H., et al. (1998) · Nature · doi:10.1038/24790 · Cited by 1,160
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Emerging principles of altered neural circuitry in schizophrenia
Benes, F. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00041-7 · Cited by 513
The postsynaptic density at glutamatergic synapses
Kennedy, M. B. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01033-8 · Cited by 475
Neurotransmitter interactions in schizophrenia–therapeutic implications
Carlsson, A., Waters, N., & Carlsson, M. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00117-1 · Cited by 298
Haroutunian, V. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1185 · Cited by 289
Self-citationPurohit, D. P., Perl, D. P., Haroutunian, V., Powchik, P., Davidson, M., & Davis, K. L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.205 · Cited by 185
Self-citationLynch, D. R., Anegawa, N. J., Verdoorn, T., & Pritchett, D. B. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10028-x · Cited by 173
Cited by
Hof, P. R., Haroutunian, V., Friedrich, V. L., Byne, W., Buitron, C., Perl, D. P., & Davis, K. L. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00237-3 · Cited by 433
Self-citationBeneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Neuroplasticity of Neocortical Circuits in Schizophrenia
Lewis, D. A., & González-Burgos, G. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301563 · Cited by 365
Pathophysiologically based treatment interventions in schizophrenia
Lewis, D. A., & Gonzalez-Burgos, G. (2006) · Nature Medicine · doi:10.1038/nm1478 · Cited by 323
Metadata
- Authors
- Dracheva, S., Marras, S. A. E., Elhakem, S. L., Kramer, F. R., Davis, K. L., & Haroutunian, V.
- Venue
- American Journal of Psychiatry
- Published
- 2001-09-01
- Volume
- 158
- Issue
- 9
- Pages
- 1400-1410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160470207
- Cited by
- 190
- References
- 14
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.